Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Rui Li, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Tianhao Zhang, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul, Kostyantyn Krysan, Aaron E Lisberg, Edward B Garon, Bin Liu, Steven M Dubinett
BACKGROUND: Despite recent advances in immunotherapy, many patients with non-small cell lung cancer (NSCLC) do not respond to immune checkpoint inhibitors (ICI). Resistance to ICI may be driven by suboptimal priming of antitumor T lymphocytes due to poor antigen presentation as well as their exclusion and impairment by the immunosuppressive tumor microenvironment (TME). In a recent phase I trial in patients with NSCLC, in situ vaccination (ISV) with dendritic cells engineered to secrete CCL21 (CCL21-DC), a chemokine that facilitates the recruitment of T cells and DC, promoted T lymphocyte tumor infiltration and PD-L1 upregulation...
September 2023: Journal for Immunotherapy of Cancer